Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cheng-Ping Mao"'
Autor:
Cheng-Ping Mao, Martin R Brovarney, Karim Dabbagh, Herbert F Birnböck, Wolfgang F Richter, Christopher J Del Nagro
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80533 (2013)
The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders. Intravenous administration of rituximab is associated with infusion times of 4-6 hours, a
Externí odkaz:
https://doaj.org/article/eeb65fc96d514282b864a98a108fedec
Autor:
Gregory R. Luedtke, Yuanying Anne Huang, Sundeep Dugar, Jose Carlos Chavez, Ramona Almirez, Sarvajit Chakravarty, Cheng Ping Mao, Ann M. Kapoun, Satyanarayana Medicherla, Gladys T. Muiru, Linda S. Higgins, Aaron N. Nguyen, Don Lim, Yu-Wang Liu, Heather K. Webb, Bruce Koppelman, Babu J. Mavunkel, Ying Feng, Andrew A. Protter
Publikováno v:
Pharmacology. 81:204-220
The effects of small-molecule p38 inhibitors in numerous models of different disease states have been published, including those of SD-282, an indole-5-carboxamide inhibitor. The aim of the present study was to evaluate the pharmacological activity o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95ddf888b5b53ad1f684ec45b5167e2d
https://doi.org/10.1159/000112865
https://doi.org/10.1159/000112865
Autor:
Christopher Del Nagro, Cheng-Ping Mao, Herbert Birnböck, Wolfgang F. Richter, Karim Dabbagh, Martin Brovarney
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 11, p e80533 (2013)
PLoS ONE, Vol 8, Iss 11, p e80533 (2013)
The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders. Intravenous administration of rituximab is associated with infusion times of 4-6 hours, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b65f9255d7b53015a2ba8004c781039
http://europepmc.org/articles/PMC3827219
http://europepmc.org/articles/PMC3827219
Publikováno v:
Chest. 117(5 Suppl 1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3d0fb8c73b5e1a2232408b3b9cd918c
https://pubmed.ncbi.nlm.nih.gov/10843926
https://pubmed.ncbi.nlm.nih.gov/10843926
Autor:
Wolfgang F. Richter, Cheng Ping Mao, Christopher Del Nagro, Karim Dabbagh, Herbert Birnboeck, Martin Brovarney
Publikováno v:
Blood. 116:3980-3980
Abstract 3980 Rituximab (MabThera)® is a chimeric mouse/human monoclonal antibody recognizing the B cell specific trans-membrane protein CD20. Rituximab's CD20 specific binding facilitates the prolonged depletion of both malignant and endogenous CD2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba9a8524efaf442553160e5420120928
https://doi.org/10.1182/blood.v116.21.3980.3980
https://doi.org/10.1182/blood.v116.21.3980.3980